Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 9/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | TEC | P42680 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763189 | 0.85 | OPRL1 (0.48) | OPRL1ALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL1364646 | 0.84 | ADAM17 (0.60) | OPRL1ADAM17MMP13 | |
| Hydrochloric Acid SCHEMBL2176855 | 0.83 | ADAM17 (0.59) | OPRL1ADAM17MMP13 | |
| Hydrochloric Acid SCHEMBL2172680 | 0.83 | ADAM17 (0.59) | OPRL1ADAM17MMP13 | |
| SCHEMBL6628522 | 0.74 | POLB (0.50) | EHMT2ALDH1A1NR4A2 | |
| SCHEMBL13059430 | 0.74 | POLB (0.50) | EHMT2ALDH1A1NR4A2 | |
| Hydrochloric Acid SCHEMBL3770405 | 0.73 | POLB (0.49) | EHMT2ALDH1A1NR4A2 | |
| SCHEMBL6632245 | 0.73 | ADAM17 (0.63) | ADAM17MMP13 | |
| SCHEMBL8353322 | 0.72 | ADAM17 (0.62) | ADAM17MMP13 | |
| SCHEMBL5887602 | 0.71 | ADAM17 (0.61) | ADAM17MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311741-A1 | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | INHIBOX LTD. (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311741-A1 | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | INHIBOX LTD. (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311741-A1 | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | INHIBOX LTD. (GB) | 2010-12-09 | — | — | US | disclosed |
| WO-2008142376-A1 | BICYCLOSULFONYL ACID (BCSA) COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | INHIBOX LTD. (GB) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311741-A1 | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | TNF, CS, COASY | EHMT2 4042/4885OPRL1 2233/4885ALDH1A1 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.